Annexon, Inc. (ANNX)
NASDAQ: ANNX · Real-Time Price · USD
2.550
+0.260 (11.35%)
At close: Sep 11, 2025, 4:00 PM EDT
2.440
-0.110 (-4.31%)
After-hours: Sep 11, 2025, 7:51 PM EDT
Annexon Employees
Annexon had 100 employees as of December 31, 2024. The number of employees increased by 29 or 40.85% compared to the previous year.
Employees
100
Change (1Y)
29
Growth (1Y)
40.85%
Revenue / Employee
n/a
Profits / Employee
-$1,887,830
Market Cap
280.21M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 100 | 29 | 40.85% |
Dec 31, 2023 | 71 | -9 | -11.25% |
Dec 31, 2022 | 80 | 19 | 31.15% |
Dec 31, 2021 | 61 | 13 | 27.08% |
Dec 31, 2020 | 48 | 24 | 100.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ANNX News
- 4 days ago - Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 days ago - Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 15 days ago - Annexon Biosciences to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 24 days ago - Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - GlobeNewsWire
- 5 weeks ago - Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy - GlobeNewsWire
- 7 weeks ago - Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy - GlobeNewsWire
- 2 months ago - Annexon: Lead GBS Therapy Stokes Near-Term Potential - Seeking Alpha